Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575374 · ClinicalTrials.gov registry record · Phase 2
Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell
A Phase 2 study of Cell Therapy, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT06575374 is a Phase 2 study of Cell Therapy that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 36 participants, below the 63-participant average among 3 other Cell Therapy trials with a reported enrollment target (43% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06575374, a Phase 2 study of Cell Therapy, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
Conditions Studied
Interventions
- DRUG Letermovir
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-12-12 |
| Est. Completion | 2027-08-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575374
The ClinicalTrials.gov registry entry for NCT06575374 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 63-participant average among 3 other Cell Therapy trials with a reported enrollment target (43% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cell Therapy appearing as the primary indexed condition, and to 1 intervention - of which Letermovir is the first listed.
NCT06575374 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06575374 about?
NCT06575374 is a clinical study titled "Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T Cell". The goal of this clinical research study is to learn if a drug called Letermovir can help to prevent CMV reactivation.
What is the current status of trial NCT06575374?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-12-12. Estimated completion is 2027-08-01.
What conditions does trial NCT06575374 study?
This clinical trial studies the following conditions: Cell Therapy.
What interventions are being tested in trial NCT06575374?
The interventions under investigation include: Letermovir (DRUG).
Who is sponsoring clinical trial NCT06575374?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06575374 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cell Therapy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Investigation of the Safety of 4 Different Doses of Autologous Muscle Derived Cells as Therapy for Stress Urinary Incontinence
COMPLETED · Phase 2
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.